23andMe Holdings (ME.Q), the California-based personal genomics and biotechnology company, made headlines on Thursday after announcing that it has begun trading on the NASDAQ through an SPAC, sponsored by…
Health Science
Rollbacks Yesterday Core One Labs (COOL.C) announced an 8:1 share rollback to prepare itself for a Nasdaq listing. Today the company has 114,600,611 common shares outstanding, after the rollback,…
Mind Cure Health (MCUR.C) announced the development of two proprietary ketamine-enhanced protocols specifically for pain management and another for depression, according to a press release. Depression is basically…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
MYND Life Sciences (MYND.C) announced they have signed a Letter of Intent (LOI) with Eyam Vaccines and Immunotherapies which outlines an Exclusive Licensing Agreement with respect to Eyam’s proprietary…
Revive Therapeutic (RVV.C) announced they have entered into an agreement with the University of Health Sciences Antigua (UHSA) to collaborate with Revive on their novel psychedelic-assisted therapies and pioneering…
PhaseBio Pharmaceuticals (PHAS.Q), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary disease, announced today that it has entered into an exclusive licensing…
Red Light Holland (TRIP.C) and Australian-based cannabis producer, Creso Pharma (COPHF.OTCQB), agreed to combine businesses today to create combined psychedelics and cannabinoid company called The HighBrid Lab, according to…
ReShape Lifesciences (RSLS.Q), a global weight-loss solutions leaders, announced today that it has completed its previously announced merger with Obalon Therapeutics, a vertically integrated medical technology company focused on…
Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Cybin demonstrated their proof of concept for…